Clinical application of comprehensive genomic profiling based on circulating tumor DNA in patients with advanced lung cancer
10.3760/cma.j.cn114452-20230226-00122
- VernacularTitle:基于循环肿瘤DNA的全景肿瘤变异分析在晚期肺癌患者中的临床应用
- Author:
Huiqin JIANG
1
;
Fei HUANG
;
Xinning CHEN
;
Minna SHEN
;
Beili WANG
;
Baishen PAN
;
Wei GUO
Author Information
1. 复旦大学附属中山医院检验科，上海200032
- Keywords:
DNA, neoplasm;
Lung neoplasms;
Comprehensive genomic profiling
- From:
Chinese Journal of Laboratory Medicine
2023;46(9):899-903
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This work aims to evaluate the clinical values of comprehensive genomic profiling examination based on circulating tumor DNA (ctDNA) in advanced lung cancer patients.Methods:This is a single-center, retrospective study that collected peripheral blood samples from patients with advanced lung cancer and performed gene mutation analysis using the TruSight Oncology 500 ctDNA assay kits. Between February 2022 and March 2023, a total of 82 patients were enrolled in Zhongshan Hospital, Fudan University, and 76 patients were included in the final analysis.According to the AMP/ASCO/CAP guidelines, mutations of targeted genes were divided into four levels (Tier I-IV), and the effectiveness of targeted therapy guided by ctDNA was evaluated. Descriptive statistics were used for basic characteristics, and the analysis of factors related to tumor mutational burden (TMB) was performed using the rank-sum test.Results:The ctDNA detection success rate was 92.7%(76/82).The median turnaround time for ctDNA testing was 10.5 days (9,13 days). At least one actionable mutation (Tier I or Ⅱ) was detected in 82.9%(63/76) of patients, and 28.6% (18/63) of patients received matched therapy, achieving a disease control rate of 18/18 and an objective response rate of 12/18.Conclusion:Comprehensive genomic profiling based on ctDNA can effectively identify actionable alterations in patients with advanced lung cancer and provide valuable information for matched therapy.
